Recombinant tissue plasminogen activator for treatment of hepatic veno-occlusive disease following bone marrow transplantation in children: Effectiveness and a scoring system for initiating treatment

Bone Marrow Transplantation

Volumn 31, Issue 7, 2003, Pages 591-597

  Bajwa, R P S ^a   Cant, A J ^a   Abinun, M ^a   Flood, T J ^a   Hodges, S ^b   Hale, J P ^b   Skinner, R ^a,b  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

Bone marrow transplantation; Children; Hepatic veno occlusive disease; Immunodeficiency; Recombinant tissue plasminogen activator

Indexed keywords

ALBUMIN; ALTEPLASE; ANALGESIC AGENT; ANTITHROMBIN III; BILIRUBIN; BUSULFAN; COMPLEMENT COMPONENT C1S INHIBITOR; CYCLOPHOSPHAMIDE; DEFIBROTIDE; DIURETIC AGENT; HEPARIN; PROSTAGLANDIN E1; UROKINASE; URSODEOXYCHOLIC ACID;

ACUTE LEUKEMIA; ARTICLE; BETA THALASSEMIA; BILIRUBIN BLOOD LEVEL; BONE MARROW TRANSPLANTATION; CAPILLARY LEAK SYNDROME; CHILD; CLINICAL ARTICLE; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; LIVER VENOOCCLUSIVE DISEASE; MALE; MULTIPLE ORGAN FAILURE; NEUROBLASTOMA; OMENN SYNDROME; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM;

BILIRUBIN; BONE MARROW TRANSPLANTATION; FOLLOW-UP STUDIES; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; INFANT; INFANT, NEWBORN; PLASMINOGEN ACTIVATORS; RECOMBINANT PROTEINS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TISSUE PLASMINOGEN ACTIVATOR; TRANSPLANTATION, AUTOLOGOUS;

EID: 0038405050     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703881     Document Type: Article

References (18)

1. Watanabe K, Iwaki H, Satoh M et al. Veno-occlusive disease of the liver following bone marrow transplantation: a clinical-pathological study of autopsy cases. Artif Organs 1996; 20: 1145-1150.
2. Lee J-H, Lee K-H, Kim S et al. Relevance of proteins C and S, antithrombin III, Von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective study. Bone Marrow Transplant 1998; 22: 883-888.
3. Bearman SI, Anderson GL, Mori M et al. Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993; 11: 1729-1736.
4. McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multi organ failure after bone marrow transplantation - a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267.
5. Kulkarni S, Rodriguez M, Lafuente A et al. Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (HVOD). Bone Marrow Transplant 1999; 23: 803-807.
6. Richardson P, Elais ED, Krishnan A et al. Treatment of severe Veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high risk population. Blood 1998; 92: 737-744.
7. Miniero R, Vassallo E, Soldano S et al. Management of hepatic veno-occlusive disease in pediatric patients: retrospective analysis in 6 AIEOP-BMT (Italian Pediatric Hematolgy Oncology Association-Bone Marrow Transplantation group) centers. Bone Marrow Transplant 1996; 18 (Suppl 2): 157-159.
8. Jones RJ, Lee KSK, Beschorer WE et al. Venocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778-783.
9. Wilkinson JD, Pollack MM, Ruttimann UE et al. Outcome of pediatric patients with multiple organ system failure. Crit Care Med 1986; 14: 271-274.
10. Nünberger W, Heying R, Burdach S et al. C1 esterase inhibitor concentrate for capillary leakage syndrome following bone marrow transplantation. Ann Hematol 1997; 75: 95-01.
11. Schriber J, Milk B, Shaw D et al. Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation. Bone Marrow Transplant 1999; 24: 1311-1314.
12. Bearman SI, Lee JL, Baron AE et al. Treatment of hepatic venoocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 1997; 89: 1501-1506.
13. Goyal RK, Wall DA, Yu LC et al. Identification of patients with hepatic venoocclusive disease likely to respond to rtPA therapy. Blood 1993; 10 (Suppl 1): 632a (abstract).
14. McDonald GB, Sharma P, Matthews DE et al. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence and predisposing factors. Hepatology 1984; 4: 116.
15. Morris JD, Harris RE, Hashmi R et al. Anti-thrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation. Bone Marrow Transplant 1997; 20: 871-878.
16. Eltumi M, Trivedi P, Hobbs JR et al. Monitoring of venoocclusive disease after bone marrow transplantation by serum aminopropeptide of type III procollagen. Lancet 1993; 342: 518-521.
17. Tanikawa S, Mori S, Ohhashi K et al. Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study. Bone Marrow Transplant 2000; 26: 881-886.
18. Salat C, Holler E, Wolf C et al. Laboratory markers of venoocclusive disease in the course of bone marrow transplantation. Bone Marrow Transplant 1997; 19: 487-490.